Published in Blood Weekly, May 20th, 1996
It also may have the potential of inhibiting a wide range of autoimmune diseases, said Janet E. Buhlmann and Randolph J. Noelle, Dartmouth Medical School, Lebanon, New Hampshire ("Therapeutic Potential for Blockade of the CD40 Ligand, gp39," Journal of Clinical Immunology, 1996;16:83-89).
"There is mounting evidence supporting a critical role for gp39-CD40 interactions in the development of both humoral and cellular immune responses," wrote Buhlmann and Noelle.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.